Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

5HT6 antagonists in the treatment of Alzheimer's dementia: current progress

Open access
Andrews, Megan, Tousi, Babak, Sabbagh, Marwan N. · 2018 · Neurology and Therapy

Abstract

Alzheimer's disease is an important condition with a considerable and unmet disease burden in large need of continued research and more treatment options. The 5HT6 antagonists are a new class of medications to be offered. Because they are pro-cholinergic, these medications are to be used as adjuncts to acetylcholinesterase inhibitors (such as donepezil), further increasing acetylcholine in the central nervous system (CNS). Early trials of the 5HT6 antagonists showed improvements in cognition and activities of daily living when used as adjuncts to current therapies for Alzheimer's dementia. However, recent phase III trials have failed to show a statistically significant improvement in cognitive function. This article will provide a comprehensive review of 5HT6 antagonists in drug development, including some that have been recently discontinued. We will discuss both the successes and failures of this drug class and provide rationale for their continued research and development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40120-018-0095-y

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 50

Metadata

Authors
Andrews, M., Tousi, B., & Sabbagh, M. N.
Affiliations
  • Creighton University (US)
  • Cleveland Clinic (US)
Corresponding author
Sabbagh, Marwan N.
Venue
Neurology and Therapy
Published
2018-05-02
Volume
7
Issue
1
Pages
51-58
ISSN
  • 2193-6536 (ISSN-L)
  • 2193-8253
OpenAlex
W2800992605
Cited by
50
References
23
Citations by year
2026: 2 · 2025: 7 · 2024: 13 · 2023: 3 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 4 · 2018: 1
FWCI
3.27
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Neurology and Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Barrow Neurological Foundation (NIA P30 AG019610)
  • National Institute on Aging (AG019610, P30AG019610)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
5-HT6 receptor antagonists, Alzheimer's disease, Alzheimer's dementia, acetylcholinesterase inhibitors, donepezil, adjunctive therapy, cognitive function, activities of daily living, phase III trial failure, drug development, drug discontinuation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 5HT6 antagonists in the treatment of Alzheimer's dementia: current progress. https://app.cochat.ai/papers/10.1007/s40120-018-0095-y
The paper
Andrews, M., Tousi, B., & Sabbagh, M. N. (2018). 5HT6 antagonists in the treatment of Alzheimer's dementia: current progress. Neurology and Therapy. https://doi.org/10.1007/s40120-018-0095-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.